FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risks

A Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimously agreed the test is safe, but the vote on effectiveness was narrower.

Panel members debated the possibility of false‑positive or false‑negative results and warned that a negative test should not replace guideline‑recommended cancer screenings. They noted the risk of false positives is low, but emphasized patients should continue existing screening protocols.

Grail has already filed a pre‑market approval application for Galleri. Analysts at Canaccord Genuity said the panel’s recommendation is a strong predictor of eventual FDA approval, underscoring the test’s potential impact on cancer detection strategies.